Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma

V. Hlavac, R. Vaclavikova, V. Brynychova, P. Dvorak, K. Elsnerova, R. Kozevnikovova, K. Raus, K. Kopeckova, S. Mestakova, D. Vrana, J. Gatek, P. Soucek

. 2021 ; 25 (1) : 99-110. [pub] 20210102

Language English Country New Zealand

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026291

Grant support
NV17-28470A MZ0 CEP Register

Digital library NLK
Full text - Article

E-resources Online Full text

NLK ProQuest Central from 2008-05-01 to 1 year ago
Health & Medicine (ProQuest) from 2008-05-01 to 1 year ago

Links

PubMed 33387348
DOI 10.1007/s40291-020-00506-2
Knihovny.cz E-resources

BACKGROUND AND OBJECTIVE: Membrane solute carrier transporters play an important role in the transport of a wide spectrum of substrates including anticancer drugs and cancer-related physiological substrates. This study aimed to assess the prognostic relevance of gene expression and genetic variability of selected solute carrier transporters in breast cancer. METHODS: Gene expression was determined by quantitative real-time polymerase chain reaction. All SLC46A1 and SLCO1A2 exons and surrounding non-coding sequences in DNA extracted from the blood of patients with breast cancer (exploratory phase) were analyzed by next-generation sequencing technology. Common variants (minor allele frequency ≥ 5%) with in silico-predicted functional relevance were further analyzed in a large cohort of patients with breast cancer (n = 815) and their prognostic and predictive potential was estimated (validation phase). RESULTS: A gene expression and bioinformatics analysis suggested SLC46A1 and SLCO1A2 to play a putative role in the prognosis of patients with breast cancer. In total, 135 genetic variants (20 novel) were identified in both genes in the exploratory phase. Of these variants, 130 were non-coding, three missense, and two synonymous. One common variant in SLCO1A2 and four variants in SLC46A1 were predicted to be pathogenic by in silico programs and subsequently validated. A SLC46A1 haplotype block composed of rs2239911-rs2239910-rs8079943 was significantly associated with ERBB2/HER2 status and disease-free survival of hormonally treated patients. CONCLUSIONS: This study revealed the prognostic value of a SLC46A1 haplotype block for breast cancer that should be further studied.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026291
003      
CZ-PrNML
005      
20211026133026.0
007      
ta
008      
211013s2021 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40291-020-00506-2 $2 doi
035    __
$a (PubMed)33387348
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Hlavac, Viktor $u Laboratory of Pharmacogenomics, Faculty of Medicine in Pilsen, Biomedical Center, Charles University, alej Svobody 76, 323 00, Pilsen, Czech Republic. viktor.hlavac@lfp.cuni.cz $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. viktor.hlavac@lfp.cuni.cz
245    10
$a SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma / $c V. Hlavac, R. Vaclavikova, V. Brynychova, P. Dvorak, K. Elsnerova, R. Kozevnikovova, K. Raus, K. Kopeckova, S. Mestakova, D. Vrana, J. Gatek, P. Soucek
520    9_
$a BACKGROUND AND OBJECTIVE: Membrane solute carrier transporters play an important role in the transport of a wide spectrum of substrates including anticancer drugs and cancer-related physiological substrates. This study aimed to assess the prognostic relevance of gene expression and genetic variability of selected solute carrier transporters in breast cancer. METHODS: Gene expression was determined by quantitative real-time polymerase chain reaction. All SLC46A1 and SLCO1A2 exons and surrounding non-coding sequences in DNA extracted from the blood of patients with breast cancer (exploratory phase) were analyzed by next-generation sequencing technology. Common variants (minor allele frequency ≥ 5%) with in silico-predicted functional relevance were further analyzed in a large cohort of patients with breast cancer (n = 815) and their prognostic and predictive potential was estimated (validation phase). RESULTS: A gene expression and bioinformatics analysis suggested SLC46A1 and SLCO1A2 to play a putative role in the prognosis of patients with breast cancer. In total, 135 genetic variants (20 novel) were identified in both genes in the exploratory phase. Of these variants, 130 were non-coding, three missense, and two synonymous. One common variant in SLCO1A2 and four variants in SLC46A1 were predicted to be pathogenic by in silico programs and subsequently validated. A SLC46A1 haplotype block composed of rs2239911-rs2239910-rs8079943 was significantly associated with ERBB2/HER2 status and disease-free survival of hormonally treated patients. CONCLUSIONS: This study revealed the prognostic value of a SLC46A1 haplotype block for breast cancer that should be further studied.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a nádory prsu $x genetika $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    12
$a genetická variace $7 D014644
650    _2
$a haplotypy $7 D006239
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a přenašeče organických aniontů $x genetika $7 D027361
650    _2
$a prognóza $7 D011379
650    _2
$a folátový přenašeč spřažený s transportem protonů $x genetika $7 D058979
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a sekvenční analýza DNA $7 D017422
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vaclavikova, Radka $u Laboratory of Pharmacogenomics, Faculty of Medicine in Pilsen, Biomedical Center, Charles University, alej Svobody 76, 323 00, Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Brynychova, Veronika $u Laboratory of Pharmacogenomics, Faculty of Medicine in Pilsen, Biomedical Center, Charles University, alej Svobody 76, 323 00, Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Dvorak, Pavel $u Laboratory of Pharmacogenomics, Faculty of Medicine in Pilsen, Biomedical Center, Charles University, alej Svobody 76, 323 00, Pilsen, Czech Republic $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Elsnerova, Katerina $u Laboratory of Pharmacogenomics, Faculty of Medicine in Pilsen, Biomedical Center, Charles University, alej Svobody 76, 323 00, Pilsen, Czech Republic
700    1_
$a Kozevnikovova, Renata $u Department of Oncosurgery, MEDICON, Prague, Czech Republic
700    1_
$a Raus, Karel $u Institute for the Care for Mother and Child, Prague, Czech Republic
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Mestakova, Sona $u Department of Surgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Vrana, David $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Gatek, Jiri $u Department of Surgery, EUC Hospital and University of Tomas Bata in Zlin, Zlin, Czech Republic
700    1_
$a Soucek, Pavel $u Laboratory of Pharmacogenomics, Faculty of Medicine in Pilsen, Biomedical Center, Charles University, alej Svobody 76, 323 00, Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic
773    0_
$w MED00163193 $t Molecular diagnosis & therapy $x 1179-2000 $g Roč. 25, č. 1 (2021), s. 99-110
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33387348 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133032 $b ABA008
999    __
$a ok $b bmc $g 1715111 $s 1146798
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 25 $c 1 $d 99-110 $e 20210102 $i 1179-2000 $m Molecular diagnosis & therapy $n Mol. diag. ther. $x MED00163193
GRA    __
$a NV17-28470A $p MZ0
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options